INS and Hypoglycemia: Other activities to reduce the attractiveness of the long-acting insulin analogue market for biosimilar manufacturers include the originator company launching more concentrated patented formulations to enhance patient convenience and potentially further reduce rates of hypoglycaemia, i.e., a 300 IU/ml formulation of insulin glargine (Gla-300) [41, 70–75].